Findings emerge from a study of hypogonadal men who underwent radiation therapy, surgery, or active surveillance for prostate cancer.
Greater visceral adipose tissue volume and density are associated with a lower the risk of biochemical recurrence.
Radiation therapy also is associated with a greater likelihood of fractures.
Does not improve overall survival in metastatic castration-resistant prostate cancer.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.
The odds of developing lethal prostate cancer were increased by 6.9 to 12.6 times for men aged 40 to 59 years with higher PSA values.
More effective tools are needed to support the long-term recovery of patients who survive cancer.
Three in 4 young or middle-aged patients receive aggressive therapies in the last months of life.
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significant prostate cancer.
Adding enzalutamide to abiraterone acetate and leuprolide acetate does not appear to be effective for the treatment of localized high-risk prostate cancer.
A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.
TURP and EBRT after seed implantation are associated with development of urge urinary incontinence.
Adding short-term androgen suppression to salvage radiotherapy may benefit men with prostate cancer who have undergone radical prostatectomy.
Most patients have unrealistic survival expectations, which may compromise their ability to make informed treatment decisions.
Patients with a relatively low tumor risk and good general health status appear to experience the best survival.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
High rates of screening for individuals with limited long-term life expectancy for all tools.
Multiple studies suggest they might.
Researchers found an adjusted 68% decreased risk of prostate cancer in men with IBD who used aminosalicylate.
Prostate cancer patients taking proton pump inhibitors also had pathologically higher stage disease.
The higher the baseline PSA levels, the greater the risk of being diagnosed with any or significant prostate cancer.
Minimally invasive surgery is associated with a lower incidence of bladder neck contracture.
Study documents superior recurrence- and metastasis-free survival compared with cT1b tumors.
A biologic effective dose less than 170 Gy2 is associated with a 2-fold increase risk dying from prostate cancer versus higher doses.
The chances of erectile function recovery improved when patients received radiation treatment more than 16 months after surgery.
In a study, use of the medication was associated with a significant 61% decreased risk.
In fact, some data suggest treatment may reduce prostate cancer incidence and aggressiveness.
The increased risk occurs more than 10 years after treatment and most pronounced in men who undergo brachytherapy.
In a study of African-American radical prostatectomy patients, low income predicted a higher risk of advanced stage or aggressive tumors.
- Testosterone Replacement Safe for Men With Prostate Cancer
- Visceral Fat Predicts Prostate Cancer Treatment Outcomes
- Cardiac Event Risk in PCa Patients Higher After Radiation Than Surgery
- Disseminated Cancer Increases Nephrectomy Complication Rate
- Subtotal Parathyroidectomy Safe, Effective, Study Finds
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)